Resonate Data Shows Consumer Economic and Health Concerns are Stabilizing
After years of rising anxiety, Americans are ready for a pause RESTON, Va., June 18, 2024 /PRNewswire/ -- Resonate, a pioneer...
COVID-19
NFID Launches New Spanish Website for Disease Prevention and Treatment
New Spanish Website Aims to Educate and Empower Patients, Caregivers, and Healthcare Professionals to Make Informed Health Decisions BETHESDA, Md.,...
Cosmos Health Strengthens Global Brain Tumor Market Position by Entering Agreement to Acquire Remaining Rights to WIPO-Filed CNS Cancer Drug Patent
CHICAGO, IL / ACCESSWIRE / June 18, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
Prenetics Announces First Quarter 2024 Financial Results
First Quarter Revenue Increased 30.2% and Gross Profit Increased 159.8% from Prior Year Quarter Confirms Strategic Pivot Targeting the U.S....
Intra-Cellular Therapies Announces Positive Topline Results in Second Phase 3 Trial Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key...
Renowned Public Health Expert Prof. Siegal Sadetzki Joins Briya
TEL AVIV, Israel, June 17, 2024 /PRNewswire/ -- Briya, a leading medical data retrieval network, proudly announces the appointment of...
Evaxion Publishes Data, Showing 67% Objective Response Rate in Metastatic Melanoma for the AI-Designed Personalized Cancer Vaccine EVX-01, in Leading Medical Journal
A 67% objective response rate (ORR) is reported in the publication summarizing results from the Phase 1 study assessing Evaxion’s...
Microbot Medical Announces Brigham and Women’s Hospital as a Site for its Pivotal Human Clinical Trial
The Site Initiation Visit for the BWH clinical staff is complete and a shipment of LIBERTY investigational units was deliveredBRAINTREE,...
Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response or better and a 71%...
Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform
The Company expects that the application for OTC clearance will shortly be followed by pursuit of POC clearance, with other...
Glaukos Announces Agreements to Exchange $230 Million in Principal Amount of Its 2.75% Convertible Senior Notes Due 2027 for Common Stock
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company, today announced that it entered into...
New Survey: 84% of Respondents Would Participate in a Hospital-at-Home Program In Order To Get Home Sooner
Vivalink's survey reveals strong consumer support for flexible care models, indicating a need for home based care as part of...
Cosmos Health Completes Acquisition of Pelofarm’s Pharmacy Distribution Network; Annual Revenue Poised to Grow by Over $5 Million
CHICAGO, IL / ACCESSWIRE / June 13, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-19 Vaccine
mRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-19 compared to...
Koda Health Secures New Funding to Expand Advance Care Planning Capabilities
Led by Ecliptic Capital with strategic investment from Memorial Hermann Health System, AARP and the Texas Medical Center Venture Fund...
Affimed Reports First Quarter 2024 Financial Results & Business Update
- Initial data from the LuminICE-203 study shows 85.7% overall response rate (ORR) (6 of 7 patients); 4 out of...
Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint
SHANGHAI, June 11, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading...
Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with Perigrove and its Portfolio Companies
PALO ALTO, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative...
Biophytis Announces the Successful Industrial Transfer of BIO101 (20-hydroxyecdysone) Production by its Service Provider Seqens
PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / June 12, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the...
Hemostemix Announces Trademark Granted by Switzerland and Interest Payment
Calgary, Alberta--(Newsfile Corp. - June 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce...